



125PERIG 211477

Roll No:

Roll number entry grid

MPHARM
(SEM I) THEORY EXAMINATION 2021-22
PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS-I

Time: 3 Hours

Total Marks: 75

Note: 1. Attempt all Sections. If require any missing data; then choose suitably.

SECTION A

1. Attempt all questions in brief. 10 x 2 = 20

- | | |
|----|---|
| a. | Differentiate between Wistar rat and Sprague Dawley rat. |
| b. | Enlist various types of bioassays. |
| c. | List the models for screening antiepileptics. |
| d. | Distinguish between homogenous and heterogeneous immunoassay. |
| e. | State the animal models for screening anti-ulcer drugs. |
| f. | Recall some methods of performing euthanasia. |
| g. | Define 'Nootropics' and name the models for its evaluation. |
| h. | State the preclinical screening models for evaluating anti-emetics. |
| i. | Compare interoceptive and exteroceptive anti-anxiety models. |
| j. | Categorize models for screening analgesics. |

SECTION B

2. Attempt any two parts of the following: 2 x 10 = 20

- | | |
|----|---|
| a. | Explain the <i>in-vitro</i> and <i>in-vivo</i> methods used for screening anti-cancer drugs. |
| b. | Discuss the pre-clinical screening methods for evaluating anti-inflammatory and anti-pyretic drugs. |
| c. | Illustrate the preclinical screening models for evaluation of antidiabetics. |

SECTION C

3. Attempt any five parts of the following: 7 x 5 = 35

- | | |
|----|--|
| a. | Discuss the animal models for screening anti-psychotics. |
| b. | Explain the production and application of transgenic animals. |
| c. | Describe the methods used for screening anti-Parkinson drugs. |
| d. | Demonstrate the immunoassay of insulin or digoxin. |
| e. | Illustrate the pre-clinical screening models for anti-hypertensive drugs. |
| f. | Define immunomodulators. Discuss the <i>in-vivo</i> and <i>in-vitro</i> models for screening them. |
| g. | Describe the CPCSEA guidelines to conduct experiments on animals. |